Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 668-675

  Gibson, C Michael ^a,b   Kirtane, Ajay J ^b   Murphy, Sabina A ^a   Rohrbeck, Steve ^c   Menon, Venu ^d   Lins, Jeffrey ^e   Kazziha, Samer ^f   Rokos, Ivan ^g   Shammas, Nicolas W ^h   Palabrica, Theresa M ⁱ   Fish, Polly ^a   McCabe, Carolyn H ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Carolina Cardiology Associates   (United States)

^d UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^e Tri State Medical Group   (United States)

^f Mount Clemens General Hospital   (United States)

^g Northridge Hospital Medical Center   (United States)

^h MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING TENDENCY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; EARLY DIAGNOSIS; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; EPICARDIUM; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NULL HYPOTHESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; ST SEGMENT ELEVATION; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART CATHETERIZATION; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; SEVERITY OF ILLNESS INDEX; SYNDROME;

EID: 33748849090     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.06.003     Document Type: Article

References (27)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
2. Gibson C.M. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. Ann Intern Med 130 (1999) 841-847
3. Nallamothu B.K., Bates E.R., Herrin J., et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111 (2005) 761-767
4. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
5. van den Merkhof L.F., Zijlstra F., Olsson H., et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 33 (1999) 1528-1532
6. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
7. Ohman E.M., Kleiman N.S., Gacioch G., et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 95 (1997) 846-854
8. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98 (1998) 734-741
9. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
10. Lee D.P., Herity N.A., Hiatt B.L., et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation 107 (2003) 1497-1501
11. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
12. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42 (2003) 1879-1885
13. Gyongyosi M., Domanovits H., Benzer W., et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur J Heart 25 (2004) 2125-2133
14. van't Hof A.W., Ernst N., de Boer M.J., et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur J Heart 25 (2004) 837-846
15. Cutlip D.E., Ricciardi M.J., Ling F.S., et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92 (2003) 977-980
16. Zorman S., Zorman D., and Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 90 (2002) 533-536
17. Cutlip DE, Cove CJ, Irons D, et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol 2001;88:A6, 62-4.
18. Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur J Heart (2005) ehi293
19. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
20. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312 (1985) 932-936
21. Gibson C.M., Cannon C.P., Murphy S.A., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101 (2000) 125-130
22. Gibson C.M., Sandor T., Stone P.H., et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol 69 (1992) 1286-1290
23. Stata Statistical Software program. Version 8.2. Stata Corporation; 2004.
24. Gibson C.M., de Lemos J.A., Murphy S.A., et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103 (2001) 2550-2554
25. Moser M., Bertram U., Peter K., et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41 (2003) 586-592
26. Ly H.Q., Kirtane A.J., Buros J., et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol 95 (2005) 383-386
27. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. The Lancet 361 (2003) 13-20